vs

Side-by-side financial comparison of BICYCLE THERAPEUTICS PLC (BCYC) and MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI). Click either name above to swap in a different company.

MARAVAI LIFESCIENCES HOLDINGS, INC. is the larger business by last-quarter revenue ($49.9M vs $48.0M, roughly 1.0× BICYCLE THERAPEUTICS PLC). BICYCLE THERAPEUTICS PLC runs the higher net margin — -42.0% vs -71.6%, a 29.5% gap on every dollar of revenue. On growth, BICYCLE THERAPEUTICS PLC posted the faster year-over-year revenue change (1193.3% vs -11.8%). BICYCLE THERAPEUTICS PLC produced more free cash flow last quarter ($-19.9M vs $-24.9M). Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs -11.9%).

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

Maravai LifeSciences Holdings is a global life sciences firm developing critical reagents, diagnostic products, and tech solutions to support biopharma research, drug development, clinical diagnostics, and cell/gene therapy manufacturing. It serves biotech, pharma, research bodies and labs worldwide across three core segments.

BCYC vs MRVI — Head-to-Head

Bigger by revenue
MRVI
MRVI
1.0× larger
MRVI
$49.9M
$48.0M
BCYC
Growing faster (revenue YoY)
BCYC
BCYC
+1205.1% gap
BCYC
1193.3%
-11.8%
MRVI
Higher net margin
BCYC
BCYC
29.5% more per $
BCYC
-42.0%
-71.6%
MRVI
More free cash flow
BCYC
BCYC
$5.0M more FCF
BCYC
$-19.9M
$-24.9M
MRVI
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
-11.9%
MRVI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCYC
BCYC
MRVI
MRVI
Revenue
$48.0M
$49.9M
Net Profit
$-20.2M
$-35.7M
Gross Margin
25.8%
Operating Margin
-51.5%
-117.9%
Net Margin
-42.0%
-71.6%
Revenue YoY
1193.3%
-11.8%
Net Profit YoY
61.1%
-37.7%
EPS (diluted)
$-0.29
$-0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCYC
BCYC
MRVI
MRVI
Q4 25
$48.0M
$49.9M
Q3 25
$11.7M
$41.6M
Q2 25
$2.9M
$47.4M
Q1 25
$10.0M
$46.9M
Q4 24
$3.7M
$56.6M
Q3 24
$2.7M
$69.0M
Q2 24
$9.4M
$69.4M
Q1 24
$19.5M
$64.2M
Net Profit
BCYC
BCYC
MRVI
MRVI
Q4 25
$-20.2M
$-35.7M
Q3 25
$-59.1M
$-25.6M
Q2 25
$-79.0M
$-39.6M
Q1 25
$-60.8M
$-29.9M
Q4 24
$-25.9M
Q3 24
$-50.8M
$-97.1M
Q2 24
$-39.8M
$-9.8M
Q1 24
$-26.6M
$-12.1M
Gross Margin
BCYC
BCYC
MRVI
MRVI
Q4 25
25.8%
Q3 25
13.6%
Q2 25
16.4%
Q1 25
16.5%
Q4 24
34.3%
Q3 24
46.7%
Q2 24
44.4%
Q1 24
40.3%
Operating Margin
BCYC
BCYC
MRVI
MRVI
Q4 25
-51.5%
-117.9%
Q3 25
-558.6%
-98.6%
Q2 25
-2965.8%
-139.8%
Q1 25
-703.7%
-104.9%
Q4 24
-66.7%
Q3 24
-2385.9%
-239.9%
Q2 24
-498.3%
-19.4%
Q1 24
-162.4%
-29.4%
Net Margin
BCYC
BCYC
MRVI
MRVI
Q4 25
-42.0%
-71.6%
Q3 25
-503.7%
-61.4%
Q2 25
-2703.8%
-83.5%
Q1 25
-608.9%
-63.9%
Q4 24
-45.8%
Q3 24
-1898.4%
-140.6%
Q2 24
-425.3%
-14.1%
Q1 24
-136.0%
-18.8%
EPS (diluted)
BCYC
BCYC
MRVI
MRVI
Q4 25
$-0.29
$-0.24
Q3 25
$-0.85
$-0.18
Q2 25
$-1.14
$-0.27
Q1 25
$-0.88
$-0.21
Q4 24
$-0.21
Q3 24
$-0.74
$-0.68
Q2 24
$-0.77
$-0.07
Q1 24
$-0.62
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCYC
BCYC
MRVI
MRVI
Cash + ST InvestmentsLiquidity on hand
$628.1M
$216.9M
Total DebtLower is stronger
$291.8M
Stockholders' EquityBook value
$610.0M
$212.4M
Total Assets
$717.6M
$770.6M
Debt / EquityLower = less leverage
1.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCYC
BCYC
MRVI
MRVI
Q4 25
$628.1M
$216.9M
Q3 25
$648.3M
$243.6M
Q2 25
$721.5M
$269.9M
Q1 25
$793.0M
$285.1M
Q4 24
$879.5M
$322.4M
Q3 24
$890.9M
$578.2M
Q2 24
$961.4M
$573.2M
Q1 24
$457.0M
$561.7M
Total Debt
BCYC
BCYC
MRVI
MRVI
Q4 25
$291.8M
Q3 25
$292.8M
Q2 25
$293.9M
Q1 25
$294.9M
Q4 24
$295.9M
Q3 24
$521.7M
Q2 24
$30.9M
$522.5M
Q1 24
$30.8M
$523.3M
Stockholders' Equity
BCYC
BCYC
MRVI
MRVI
Q4 25
$610.0M
$212.4M
Q3 25
$618.5M
$245.4M
Q2 25
$668.9M
$265.9M
Q1 25
$740.3M
$300.6M
Q4 24
$793.1M
$325.3M
Q3 24
$831.0M
$344.9M
Q2 24
$873.8M
$434.7M
Q1 24
$356.0M
$410.7M
Total Assets
BCYC
BCYC
MRVI
MRVI
Q4 25
$717.6M
$770.6M
Q3 25
$764.0M
$849.2M
Q2 25
$832.2M
$897.0M
Q1 25
$883.9M
$959.8M
Q4 24
$956.9M
$1.0B
Q3 24
$996.7M
$1.3B
Q2 24
$1.1B
$1.4B
Q1 24
$547.1M
$1.4B
Debt / Equity
BCYC
BCYC
MRVI
MRVI
Q4 25
1.37×
Q3 25
1.19×
Q2 25
1.11×
Q1 25
0.98×
Q4 24
0.91×
Q3 24
1.51×
Q2 24
0.04×
1.20×
Q1 24
0.09×
1.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCYC
BCYC
MRVI
MRVI
Operating Cash FlowLast quarter
$-19.3M
$-22.8M
Free Cash FlowOCF − Capex
$-19.9M
$-24.9M
FCF MarginFCF / Revenue
-41.5%
-49.9%
Capex IntensityCapex / Revenue
1.2%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-252.0M
$-70.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCYC
BCYC
MRVI
MRVI
Q4 25
$-19.3M
$-22.8M
Q3 25
$-71.2M
$-15.2M
Q2 25
$-72.8M
$-10.3M
Q1 25
$-86.4M
$-9.4M
Q4 24
$-164.7M
$-14.6M
Q3 24
$-39.8M
$13.1M
Q2 24
$-44.6M
$17.4M
Q1 24
$-70.9M
$-8.5M
Free Cash Flow
BCYC
BCYC
MRVI
MRVI
Q4 25
$-19.9M
$-24.9M
Q3 25
$-71.8M
$-18.1M
Q2 25
$-73.3M
$-13.1M
Q1 25
$-87.0M
$-14.6M
Q4 24
$-166.0M
$-20.5M
Q3 24
$-40.3M
$4.5M
Q2 24
$-45.0M
$7.9M
Q1 24
$-70.9M
$-14.1M
FCF Margin
BCYC
BCYC
MRVI
MRVI
Q4 25
-41.5%
-49.9%
Q3 25
-612.3%
-43.4%
Q2 25
-2509.7%
-27.7%
Q1 25
-871.7%
-31.2%
Q4 24
-4475.7%
-36.2%
Q3 24
-1504.7%
6.6%
Q2 24
-481.2%
11.4%
Q1 24
-362.9%
-22.0%
Capex Intensity
BCYC
BCYC
MRVI
MRVI
Q4 25
1.2%
4.2%
Q3 25
5.7%
7.0%
Q2 25
17.1%
6.1%
Q1 25
6.1%
11.2%
Q4 24
33.3%
10.3%
Q3 24
16.3%
12.4%
Q2 24
4.5%
13.8%
Q1 24
0.1%
8.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCYC
BCYC

Segment breakdown not available.

MRVI
MRVI

Cygnus Segment$27.2M54%
Other$18.4M37%
Shipping And Handling$4.3M9%

Related Comparisons